Market Overview

Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results

Share:
Related GILD
What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
5 NASDAQ Healthcare Stocks With The Highest EPS
Actavis' Viberzi Gets FDA Nod for Irritable Bowel Syndrome - Analyst Blog (Zacks)

In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating and $61.00 price target on Gilead Sciences (NASDAQ: GILD).

In the report, Oppenheimer noted, “GILD reported initial ph.II results evaluating idelalisib (PI3K inhibitor) monotherapy in refractory indolent NHL. The results were within our expectations with idelalisib producing a 53.6% ORR, generally consistent with that seen in the prior ph.I single-agent study. We believe these results are compelling, given the study's heavily refractory patient population (~4 median prior therapies). Further, we believe this level of efficacy remains generally competitive with other investigational agents for NHL. Idelalisib's main area of uncertainty remains around its market potential, given the crowding NHL/CLL space. We currently model very conservative peak idelalisib sales of ~$700M in NHL/CLL, but see the potential for meaningful upside. We reiterate Outperform.”

Gilead Sciences closed on Friday at $52.23.

Latest Ratings for GILD

DateFirmActionFromTo
Apr 2015OppenheimerAssumesOutperform
Feb 2015Credit SuisseDowngradesOutperformNeutral
Feb 2015CitigroupMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: David Ferreiro OppenheimerAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GILD)

Around the Web, We're Loving...